Full-Time
Updated on 5/26/2026
Develops ready-to-use liquid-stable injectables
$180k - $240k/yr
Chicago, IL, USA
Hybrid
Minimum of three days per week in-office required.
Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.
Company Size
201-500
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2005
Help us improve and share your feedback! Did you find this helpful?
People at Xeris Pharmaceuticals who can refer or advise you
Health Insurance
Paid Vacation
401(k) Retirement Plan
401(k) Company Match
Remote Work Options
Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS
Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.
Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.
I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.
The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.